Skip to main content
Andrew Leavitt, MD, Hematology, San Francisco, CA

Andrew D. Leavitt MD

Blood Banking & Transfusion Medicine, Clotting Disorder, Hemophilia & Bleeding Disorder


Professor, Laboratory Medicine, UCSF School of Medicine

Join to View Full Profile
  • 505 Parnassus AveSan Francisco, CA 94143

  • Phone+1 415-514-3432

  • Fax+1 415-514-3433

Dr. Leavitt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1988 - 1989
  • University of Michigan
    University of MichiganResidency, Internal Medicine, 1986 - 1988
  • University of Michigan
    University of MichiganInternship, Internal Medicine, 1984 - 1985
  • Harvard Medical School
    Harvard Medical SchoolClass of 1984

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1989 - 2025
  • MI State Medical License
    MI State Medical License 1987 - 1991
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Publications & Presentations

PubMed

Abstracts/Posters

  • Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial
    Andrew D. Leavitt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patien...
    Andrew D. Leavitt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms
    Andrew D. Leavitt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Phlebitis after Parenteral Iron Sucrose Administration in Postpartum Women 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Pfizer’s Gene Therapy for Rare Genetic Bleeding Disorder Succeeds in Late-Stage Trial
    Pfizer’s Gene Therapy for Rare Genetic Bleeding Disorder Succeeds in Late-Stage TrialJuly 24th, 2024
  • UCSF Treats Man Who Developed Rare Blood Clot After Johnson and Johnson Vaccine
    UCSF Treats Man Who Developed Rare Blood Clot After Johnson and Johnson VaccineApril 30th, 2021
  • Bay Area Patient Is First MAN to Get Blood Clot After J&J Vaccination
    Bay Area Patient Is First MAN to Get Blood Clot After J&J VaccinationApril 26th, 2021
  • Join now to see all

Grant Support

  • Molecular Mechanisms Of TPO Induced MPL Signaling In MegakaryocytesNational Heart, Lung, And Blood Institute2001–2005
  • Novel Systems For The Study Of MegakaryocytopoiesisNational Heart, Lung, And Blood Institute1996–2000

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: